Diagnostic assessment of the developmental potential of human cryopreserved ovarian tissue from multiple patients using xenografting

Gook, Debra A.; Edgar, David; Borg, Jessica; Archer, J.; McBain, John

doi:10.1093/humrep/deh550

Cited by 106 publications

(58 citation statements)

References 47 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Thus, optimal follicle yield is of paramount importance. Although follicle density was determined from a single biopsy and distribution varies throughout the ovary, the follicle densities for the HL patients are similar to those observed for a group of young women with other types of cancer (Gook et al, 2005). Whether a single biopsy of an ovary is adequate to exclude HL involvement of the entire ovary is uncertain and one should consider random examination of several slices within the biopsy specimen prior to autotransplantation of the remaining tissue.…”

Section: Discussionmentioning

confidence: 79%

Lack of evidence of disease contamination in ovarian tissue harvested for cryopreservation from patients with Hodgkin lymphoma and analysis of factors predictive of oocyte yield

et al. 2006

View full text Add to dashboard Cite

Ovarian cryopreservation is a promising technique to preserve fertility in women with Hodgkin lymphoma (HL) treated with chemotherapy. Thus, the aim of this study was to examine harvested ovarian tissue for subclinical involvement by HL by morphology/ immunohistochemistry, and to define patient and treatment factors predictive of oocyte yield. This was a retrospective analysis of 26 ovarian tissue samples harvested for cryopreservation from women with HL. Histology, immunohistochemistry and follicle density (number mm À3 ) was examined. Disease status and preharvest chemotherapy details were obtained on 24 patients. The median age was 22 years (range 13 -29). Seven of 24 patients had infradiaphragmatic disease at time of harvest. Nine of 20 patients had received chemotherapy preharvest (ABVD (Adriamycin s , Bleomycin, Vinblastine and Dacarbazine) ¼ 7, other regimens ¼ 2). The seven receiving ABVD showed no difference in follicle density compared to patients not receiving treatment (n ¼ 14); (median ¼ 1555 vs 1620 mm 3 P ¼ 0.97). Follicle density measurement showed no correlation with patient age (R 2 ¼ 0.0001, P ¼ 0.99). There was no evidence of HL involvement in the 26 samples examined (95% CI ¼ 0 -11%). In conclusion, subclinical involvement of HL has not been identified in ovarian tissue, even when patients have infradiaphragmatic disease. Furthermore, the quality of tissue harvested does not appear to be adversely affected by patient's age or prior ABVD chemotherapy.

show abstract

Section: Discussionmentioning

confidence: 79%

Lack of evidence of disease contamination in ovarian tissue harvested for cryopreservation from patients with Hodgkin lymphoma and analysis of factors predictive of oocyte yield

et al. 2006

View full text Add to dashboard Cite

show abstract

“…Histological evaluation and follicle count performed on cortical tissue samples prior to cryopreservation is not a reliable method to quantify follicular density due to follicle clustering [23,43,53] and subsequent heterogeneity in analyzed samples [7]. Nevertheless, anatomopathological evaluation remains an essential tool, yielding an initial analysis of the presence of follicles, as well as the presence or absence of malignant cells.…”

Section: Histologymentioning

confidence: 99%

A review of 15 years of ovarian tissue bank activities

Dolmans

Jadoul

Gilliaux

et al. 2013

J Assist Reprod Genet

109

View full text Add to dashboard Cite

Purpose To review 15 years of activities in ovarian tissue cryobanking from medical database files, including patient indications, histological evaluation and clinical characteristics. Methods Retrospective longitudinal analysis of data from an ovarian tissue bank in an academic hospital. Five hundred and eighty-two patients had their ovarian tissue cryobanked between April 1997 and January 2012. Analysis of cryobanking database: precryopreservation patient characteristics, indications and safety issues, laboratory files and postcryopreservation clinical data. Results Of the 582 patients who had their ovarian tissue cryopreserved, 106 patients donated for research purposes and 476 patients for fertility preservation and long-term cryopreservation. Clinical data analysis of the 476 patients revealed a mean age at the time of cryopreservation of 23± 8.5 years (range: 9 months -39 years), with 96.2 % of subjects aged ≤35 years (n=458). Among 391 cases of malignant disease, hematological malignancies (39.9 %, n=156) and breast cancer (21.7 %, n=85) were the two main indications.At histology, malignant cells were found in ovarian tissue from leukemia patients (n = 3) and non-Hodgkin's lymphoma patients (n=2). Eleven patients underwent autotransplantation, resulting in 5 live births and 1 ongoing pregnancy. Conclusion This is the largest and most comprehensive study to describe and analyze indications and clinical patient characteristics before and after ovarian tissue cryopreservation. The procedure is safe, easy and promising. The database concept is a useful tool in patient selection for autotransplantation.

show abstract

“…Xenografting has been used to demonstrate the viability of cryopreserved ovarian tissue (Newton et al 1996, Gook et al 2005 but is not currently considered appropriate for therapy. It is widely recognised that only few men who have cryopreserved sperm prior to chemotherapy return to request use of the stored samples (Audrins et al 1999, Blackhall et al 2002 and it remains to be seen whether this may also be true in women.…”

Section: )mentioning

confidence: 99%

Ovarian cryopreservation for fertility preservation: indications and outcomes

Anderson¹,

Wallace²,

Baird³

2008

Reproduction

119

View full text Add to dashboard Cite

Female fertility preservation provides significantly different challenges to that for the male, with the only established method being cryopreservation of embryos thus necessitating the involvement of a male. Other, experimental, options include oocyte or ovarian tissue cryopreservation. The latter has been regarded as a potential method for more than a decade, but has resulted in the birth of only five babies. It is not possible to be certain how many women have had ovarian tissue cryopreserved. Oocyte cryopreservation also remains experimental, but w100-fold more babies have been born through this technique over the last two decades. Ovarian tissue cryopreservation has the potential advantages of preservation of a large number of oocytes within primordial follicles, it does not require hormonal stimulation when time is short and indeed may be appropriate for the pre-pubertal. Disadvantages include the need for an invasive procedure, and the uncertain risk of ovarian contamination in haematological and other malignancies. We here review this approach in the context of our own experience of 36 women, highlighting issues of patient selection especially in the young, and uncertainties over the effects of cancer treatments on subsequent fertility. Of these 36 women, 11 have died but 5 have had spontaneous pregnancies. So far, none have requested reimplantation of their stored ovarian tissue. Ovarian cryopreservation appears to be a potentially valuable method for fertility preservation, but the indications and approaches best used remain unclear.Reproduction (2008) 136 681-689

show abstract

Diagnostic assessment of the developmental potential of human cryopreserved ovarian tissue from multiple patients using xenografting

Cited by 106 publications

References 47 publications

Lack of evidence of disease contamination in ovarian tissue harvested for cryopreservation from patients with Hodgkin lymphoma and analysis of factors predictive of oocyte yield

Lack of evidence of disease contamination in ovarian tissue harvested for cryopreservation from patients with Hodgkin lymphoma and analysis of factors predictive of oocyte yield

A review of 15 years of ovarian tissue bank activities

Ovarian cryopreservation for fertility preservation: indications and outcomes

Contact Info

Product

Resources

About